Advertisement
Australia markets close in 2 hours 58 minutes
  • ALL ORDS

    8,103.90
    -46.20 (-0.57%)
     
  • ASX 200

    7,833.60
    -47.70 (-0.61%)
     
  • AUD/USD

    0.6664
    -0.0016 (-0.24%)
     
  • OIL

    79.25
    +0.02 (+0.03%)
     
  • GOLD

    2,379.70
    -5.80 (-0.24%)
     
  • Bitcoin AUD

    98,105.36
    -726.07 (-0.73%)
     
  • CMC Crypto 200

    1,375.79
    -18.26 (-1.31%)
     
  • AUD/EUR

    0.6134
    -0.0005 (-0.07%)
     
  • AUD/NZD

    1.0906
    0.0000 (0.00%)
     
  • NZX 50

    11,669.02
    -59.04 (-0.50%)
     
  • NASDAQ

    18,557.96
    -38.69 (-0.21%)
     
  • FTSE

    8,438.65
    -7.15 (-0.08%)
     
  • Dow Jones

    39,869.38
    -38.62 (-0.10%)
     
  • DAX

    18,738.81
    -130.55 (-0.69%)
     
  • Hang Seng

    19,391.63
    +15.10 (+0.08%)
     
  • NIKKEI 225

    38,782.08
    -138.18 (-0.36%)
     

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Eton Pharmaceuticals
Eton Pharmaceuticals

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:

Date:

Monday, May 13, 2024

 

 

Time:

10:00am ET

 

 

Webcast:

Click Here 

 

 

To schedule a 1x1 meeting with the Company, please contact your Citizens JMP institutional sales representative.

ADVERTISEMENT

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has five commercial rare disease products: ALKINDI SPRINKLE®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.

Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

Source: Eton Pharmaceuticals.